Amendments to the Specification:

Please replace paragraph [0023] with the following amended paragraph:

[0023] Enfamil® Natalins® RX multivitamin and multimineral supplement, available from Mead Johnson Nutritionals, Mead Johnson & Company, provides 4000 I.U. **[[**I .U.**]]** of vitamin A, 80 mg of vitamin C, 400 I.U. of vitamin D, 15 I.U. of vitamin E, 1.5 mg of thiamin, 1.6 mg of riboflavin, 17 mg niacin, 4 mg of vitamin B_6, 1 mg of folic acid, 2.5 mcg of vitamin B_{12}, 30 mcg of biotin, 7 mg of pantothentic acid, 200 mg of calcium, 54 mg of iron, 25 mg of zinc, and 3 mg of copper per dose. Enfamil® Natalins® RX are formulated to **[[**Ato**]]** supplement the diet during pregnancy of lactation and are available only in tablet form. See Id. at 1692.

Please replace paragraph [0056] with the following amended paragraph:

[0056] It is difficult to quantify the minimizing effect upon unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty swallowing or ingesting of the soft gelatin nutritional agents. However, the average healthy pregnant woman suffering from the normal gastrointestinal disturbances associated with pregnancy, i.e., uncomplicated incidences of heartburn, gastroesophageal reflux, dyspepsia, nausea, regurgitation, gagging, and the like, without limitation, may be able to minimize these symptoms through use of the present formulations. Furthermore, even for pregnant women who are experiencing gastrointestinal disturbances to a more pronounced than what would be classified as normal may find the formulations of the present inventive subject matter have a positive effect upon these symptoms, particularly where the gastrointestinal distress is caused or exacerbated by the ingestion of traditional vitamin and mineral tablets or where their condition has made it impossible to ingest traditional tablet form prenatal supplements.

Please replace paragraph [0059] with the following amended paragraph:

[0059] The compositions of the present inventive subject matter include essential fatty acids. Essential fatty acids are any biologically useful fatty acid, and may include polyunsaturated short, medium or long chain fatty acids, omega-3, omega-6, and omega-9 fatty acids as well as precursors and derivatives of any fatty acid, such as omega-3, omega-6, and omega-9 fatty acids. Such fatty acids and precursors include arachidonic acid, eicosapentanoic acid, docosahexaenoic ~~docosahexanoic~~ acid, oleic acid, linolenic acid, and linoleic acid. Fatty acids of the present invention may be from any source, including, without limitation, natural or synthetic oils, fats, waxes or combinations thereof. Moreover, the fatty acids herein may be derived, without limitation, form nonhydrogenated oils, partially hydrogenated oils, fully hydrogenated oils, or combinations thereof. Non-limiting ~~Nonlimiting~~ exemplary sources of fatty acids include seed oil, fish or marine oil, canola oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nut oil, palm oil, low erucic rapeseed oil, palm kernel oil, lupin oil, coconut oil, flaxseed oil, evening primrose oil, jojoba oil, tallow, beef tallow, butter, chicken fat, lard, dairy butter fat, shea butter, or combinations thereof. Specific non-limiting exemplary fish or marine oils include shell fish oil, tuna oil, mackerel oil, salmon oil, menhaden

oil, anchovy oil, herring oil, trout oil, sardine oil, oils derived from seaweed or kelp, or combinations thereof.

Please replace paragraph [0065] with the following amended paragraph:

[0065] In another preferred, non-limiting ~~non4imiting~~ aspect of the present inventive subject matter, the slightly soluble iron salts are selected from the group consisting of ferric acetate, ferric fluoride, ferric phosphate, ferric pyrophosphate, ferrous pyrophosphate, ferrous carbonate saccharated, ferrous carbonate mass, ferrous succinate, ferrous citrate, ferrous tartrate, ferric fumarate, ferric succinate, ferrous hydroxide, ferrous nitrate, ferrous carbonate, ferric sodium pyrophosphate, ferric tartrate, ferric potassium tartrate, ferric subcarbonate, ferric glycermphosphate, ferric saccharate, ferric hydroxide saccharate, ferric manganese saccharate, ferrous ammonium sulfate, other pharmaceutically acceptable iron salts, and combinations thereof. As discussed above, these iron salts may be encapsulated if a non-reactive iron is desired.

Please replace paragraph [0075] with the following amended paragraph:

[0075] The first fatty acid compound is selected from the group consisting of a linoleic acid compound, a linolenic acid compound, derivatives thereof and combinations thereof. In an illustrative, non-limiting embodiment the present composition contains at least two fatty acid compounds. ~~linolenic acid compound, derivatives thereof and combinations thereof.~~ In one embodiment the first fatty acid compound preferably comprises about 10 mg to about 1000 mg, with about 50 mg to about 500 mg being more preferred and about 100 mg to about 300 mg being most preferred.